Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Plasma cell 3Sarcoma 2Breast 1

Conditions

Prostatic Neoplasms 4

Interventions

Docetaxel 409pembrolizumab 332Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
samarium Sm-153 lexidronam × Genitourinary × Clear all
NCT00328614 2025-05-16

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Thomas Jefferson University

Phase 1 Completed
32 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00551525 2017-07-25

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

Radiation Therapy Oncology Group

Phase 2 Completed
67 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00450619 2017-01-04

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
44 enrolled 18 charts
Genitourinary

Prostatic Neoplasms

NCT00121095 2007-12-21

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

Cytogen Corporation

Phase 1/2 Unknown
69 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡